

REC

04-04-2005

ET

U.S. Department of Commerce
Patent and Trademark Office



TO: Mail Stop Assignments, Director,
Please record the attached original document(s) or copy(ies).

102971659

1450, Alexandria, VA 22313-1450

1. Name of conveying party(ies) and execution date:

Jenapharm GmbH & Co., KG

Execution Date
March 25, 2004

Additional name(s) of conveying party(ies) attached?

☐ Yes

☒ No

2. Name and address of receiving party(ies):

Name: Schering AG

Street Address: Müllerstr. 1778,

City: Berlin

Country: Germany

Zip: 13353

Additional name(s) address(es) attached?

☐ Yes

☒ No.

2005 MAR 31 AM 7:20
OPR/FINANCE

3. Nature of conveyance:

☒ Assignment

☐ Merger

☐ Security Agreement

☐ Change of Name

☐ Other:

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application Number(s):

B. Patent Number(s):

6,080,735

Additional numbers attached: ☐ Yes ☒ No

5. Name and address of party to whom
correspondence concerning document should be
mailed:

Wood, Phillips, Katz, Clark & Mortimer
Citicorp Center, Suite 3800
500 West Madison Street
Chicago, Illinois 60661-2511
Phone: (312) 876-1800

6. Total number of applications and patents involved: 1

7. Total Fee (37 CFR 3.41) \$ 40.00

☒ Enclosed

☐ Authorized to charge Deposit Account

8. Deposit Account No.: 23-0785

DO NOT USE THIS SPACE

9. SIGNATURE

John S. Mortimer, 30,407

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachment, and documents: 1

04/01/2005 ECOOPER 00000165 6080735

01 FC:0021

40.00 OP

PATENT
REEL: 016397 FRAME: 0958

ASSIGNMENT

This Agreement is effective this 25th day of March, 200~~4~~⁷, by and between Jenapharm GmbH & Co. KG, a German corporation, having an address of Ottogerd-Mühlmann-Straße 17, 07743 Jena, Germany (hereinafter "Jenapharm"), and Schering AG, a German corporation, having an address of Müllerstr. 178, 13353 Berlin, Germany (hereinafter "Schering").

Whereas Jenapharm is the exclusive owner of U.S. Patent No. 6,080,735 entitled "Estra-1,3,5(10)-Triene Derivatives, Processes for Their Preparation and Pharmaceutical Compositions Containing These Compounds", issued June 27, 2000 (hereinafter the "Patent").

Whereas, Schering is desirous of acquiring the Patent.

NOW, THEREFORE, for \$1.00 and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Jenapharm does hereby assigned unto Schering its entire right, title and interest it has in and to the Patent.

2. IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

JENAPHARM GMBH & CO., KG

By: [Signature]

Name: Isabel Rothe

Title: Managing Director

By: [Signature]

Name: Holger Lehmann

Title: Head of Finance and Accounting

SCHERING AG

By: [Signature]

Name: Dr. Noeske-Jungblut

Title: European Patent Attorney

By: [Signature]

Name: Dr. Schwarz

Title: Patent Professional